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Phosphatidylinositol 3-kinase (PI3-kinase) controls mitogenesis, cellular growth and 
transformation in a variety of cancers.  The serine-threonine kinase Akt is a down-
stream target of PI3-kinase, and phosphorylated Akt (Phospho-Akt) inhibits apoptosis. 
Phosphatase and tensin homolog detected on chromosome ten (PTEN) is a tumor sup-
pressor that antagonizes PI3-kinase activity, negatively regulates its downstream-target, 
Akt, inhibits phosphorylation of Akt, and medicates cell-cycle arrest and apoptosis.  To 
clarify whether the PI3-kinase/Akt pathway and PTEN relate to breast cancer, we exam-
ined the expression of pathway-related proteins such as Phospho-Akt and PTEN in clini-
cal specimens.  Immunohistochemical analysis was performed on tissue specimens sur-
gically obtained from 221 patients with breast cancer.  The association of Phospho-Akt 
and PTEN expression with clinicopathological variables and the prognosis of patients 
were analyzed.  Of 221 breast carcinomas, positive Phospho-Akt expression was ob-
served in 91 (41.1%) and positive PTEN expression in 119 (53.8%).  Phospho-Akt expres-
sion and loss of PTEN expression signiﬁcantly correlated with tumor staging, tumor size 
and lymph node metastasis.  Patients with Phospho-Akt-positive tumors had signiﬁcant-
ly inferior disease-free survival or over-all survival to those with Phospho-Akt-negative 
tumors, while those with PTEN positive tumors were better than those with PTEN nega-
tive tumors.  Moreover, patients with Phospho-Akt-positive and PTEN-negative tumors  
had a signiﬁcantly inferior disease-free survival and over-all survival compared to those 
with Phospho-Akt-negative and PTEN-positive tumors.  Multivariate analysis revealed 
that expression of Phospho-Akt and tumor size were the independent factors (P = 0.024). 
We demonstrated that the expression of Phospho-Akt signiﬁcantly correlated with tumor 
progression and patients survival with breast cancer.  Phospho-Akt/PTEN expression 
status is possibly a deﬁnitive prognostic factor in clinical breast cancer. 
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Aberrant functions of phosphatidylinositol 
3-kinase (PI3-kinase) contribute to mitogenesis, 
cellular growth and transformation in a variety 
of cancers including breast cancer (Carpenter et 
al., 1990; Varticovski et al., 1994).  PI3-kinase 
is activated by insulin, various growth factors 
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and cytokines (Burgering and Coffer, 1995),  and 
catalyzes the phosphorylation of inositol phos-
pholipids at the 3 position to generate phosphati-
dylinositol 3,4,5-trisphosphate and phosphatidyli-
ositol 3,4-bisphosphate.  Serine-threonine kinase 
Akt is a downstream target of PI3-kinase.  Akt is 
phosphorylated at Thr-308 and Ser-473 by PI3-
kinase, thus Akt is converted to phosphorylated 
Akt (Phospho-Akt) (Franke et al., 1997), which 
phosphorylates BAD, caspase-9, Forkhead tran-
scription factors and IκB kinase α which correlate 
with apoptosis (Datta et al., 1997; Ozes et al., 
1999).  Akt has also been shown to inhibit the 
Raf-MEK-ERK pathway through phosphorylation 
of Raf-1 in myotubes, and to overcome constitu-
tively activated MAPK-induced cell-cycle arrest 
in MCF7 cells (Rommel et al., 1999).  Akt is thus 
an important regulator of cell proliferation and 
survival.  Amplification of genes encoding Akt 
isoforms has been found in several types of hu-
man cancers.  Phospho-Akt plays an important 
role in the development and/or progression of a 
subset of human cancers. 
 In addition, mutations in the phosphatase 
and tensin homolog deleted on chromosome ten 
(PTEN), one of the most frequently mutated 
tumor suppressor genes on 10q23.3, results in 
elevated Akt activity.  Germline mutations of 
PTEN/MMAC1/TEP1 has been reported to cor-
relate with Cowden syndrome, Bannayan-Riley-
Ruvalcade, proteus and proteus-like syndromes 
(Marsh et al., 1999; Zhou et al., 2001).  PTEN 
antagonizes PI3-kinase activity, negatively regu-
lates its downstream-target Akt and mediates cell-
cycle arrest and apoptosis.  Speciﬁcally, cell line 
analyses have shown that PTEN appears to sup-
press breast cancer growth by down-regulation of 
PI3-kinase, with resultant G1 arrest and cell death 
(Weng et al., 1999).  Studies of embryonic stem 
cells have shown that cells featuring mutations 
of the PTEN gene exhibited an increased growth 
rate and an advanced entry into S-phase (Sun et 
al., 1999).  The accelerated G1/S transition was 
accompanied by down-regulation of p27, a major 
inhibitor of G1 cyclin-dependent kinases.  Over-
all, results have demonstrated that PTEN regu-
lates cell cycle progression and survival. 
 Breast cancer is the most common cancer in 
women, accounting for about 30% of all female 
malignancies, and is a major cause of morbidity 
and mortality in the female population (Landis et 
al., 1998).  In this report, to clarify whether the 
PI3-kinasse/Akt pathway and PTEN are related 
to breast cancer, we examined the expression of 
pathway-related proteins such as Phospho-Akt 
and PTEN in clinical specimens of breast can-
cer.
 
Materials and Methods
Specimen collection
Specimens, embedded in parafﬁn, which had been 
collected from patients with breast cancer who 
underwent surgery at Tottori University Hospital, 
Yonago, and Tottori Red Cross Hospital, Tottori, 
between 1987 and 2002, were examined.  There 
were 221 post-operated patients, aged from 25 to 
87 years (mean, 55.5), with a mean follow-up of 
67.8 months (range, 7–180).  Fifty-three (23.9%) 
patients had a relapse and 35 (15.8%) died of the 
cancer, while 176 (79.6%) were alive at the time of 
the completion of the study (August 2003).  Can-
cer was residual in 8 patients and the disease free 
survival of 13 patients was unknown.  Eighty-one 
(41.2%) patients were at stage I, 59 (26.7%) stage 
IIA, 34 (15.4%) stage IIB, 27 (12.2%) stage IIIA, 
1 (0.5%) stage IIIB and 9 (4.1%) stage IV.  The 
clinicopathological ﬁndings were determined ac-
cording to tumor-node-metastasis (Stmad, 1999). 
The patients were given adjuvant chemotherapy 
according to St. Gallen recommendations from 
1998.
 
Histopathological examination
Resected specimens were fixed in 10% buffered 
formalin for 48 h, and then were cut into 5-mm 
slices.  Slices were embedded in parafﬁn, and the 
tissue parafﬁn blocks were cut into 4-µm-thick sec-
tions for hematoxylin-eosin and immunostaining. 
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Immunohistochemistry for Phospho-Akt 
and PTEN
The 4 µm-thick sections were dewaxed using xy-
lene and transferred to alcohol.  Deparaffinized 
Fig. 1.  Immunohistochemical staining patterns for Phospho-Akt expression in breast cancer. 
Phospho-Akt antigen exists in both the cytoplasm and nucleus (× 100).
Fig. 2.  PTEN expression in breast cancer. PTEN expression is found in the cytoplasm (× 100).
tissue sections underwent antigen retrieval with 
the target retrieval solution at pH 6.1 (Dako, 
Grostrup, Denmark) in an autoclave at 120˚C for 
15 min.  The slides for immunohistochemistry for 
PTEN were placed in citric acid buffer (10 mM) 
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and heated in an autoclave at 120˚C for 15 min. 
Endogenous peroxidase activity was blocked by 
incubating sections with 0.3% hydrogen perox-
ide in methanol for 10 min at room temperature. 
Slides were then washed 3 times in phosphate-
buffered saline (PBS) and incubated in 10% 
normal goat serum for 1 h to reduce nonspeciﬁc 
antibody binding.  Then slides were incubated 
overnight at 4˚C with the following primary an-
tibodies: polyclonal antibodies raised against 
Phospho-Akt  (Ser 473) (diluted 1:50; Cell Signal-
ing Technology, Danvers, MA) and PTEN (diluted 
1:100; Upstate Biotechnology, Lake Placid, NY). 
After washing the slides with PBS, biotinylated 
antibodies were applied as second antibody: anti-
rabbit immunoglobulin (IgG + IgA + IgM) conju-
gated with biotin for 1 h , followed by incubation 
with a sterptvidin-peroxidase complex (Histoﬁne 
ABC kit; Nichirei, Tokyo, Japan) for 1 h at room 
temperature.  The reaction products were visual-
ized with diaminobenzidine as the chromogen and 
the slides were counterstained with hematoxylin. 
All immunostained sections were evaluated in a 
blinded manner with no knowledge of the clinical 
and pathological factors.  Intensity is designated 
as negative when less than 5% of tumor cells are 
stained and positive when over 5% of tumor cells 
are stained.
Statistical analysis 
The χ2 test was used to determine the signiﬁcance 
of the association between different variables. 
The comparison of Phospho-Akt and PTEN ex-
pression with disease-free survival and over-all 
survival were performed by univariate and multi-
variate analysis using the Kaplan-Meier test and 
Cox proportion hazard model.  The level of sig-
niﬁcance was set at P < 0.05.
 
Results
Phospho-Akt and PTEN expression 
The immunoreactivity of Phospho-Akt was pre-
dominantly observed in the cytoplasm and the 
nucleus (Fig. 1).  The expression of Phospho-Akt 
protein was seen in 91 (41.1%) of the breast tu-
mors.  Phospho-Akt expression signiﬁcantly cor-
related with staging, tumor size and lymph node 
metastasis (Table 1).  PTEN expression was found 
in the cytoplasm of breast cancer cells; shown 
in Fig. 2.  Of the 221 breast tumors, 119 (53.8%) 
showed PTEN protein expression, which signiﬁ-
cantly correlated inversely with tumor stage, tu-
Table 1.  Immunohistochemical staining for Phospho-Akt and PTEN in relation to the clinical 
stage in the current study
Variable   Phospho-Akt  PTEN
 Negative  Positive P value Negative Positive P value 
Age  60.7 ± 10.6 48.6 ± 10.4 < 0.05  56.0 ± 14.0 54.7 ± 10.3   0.96
Size
     2 cm ≥ 80 31 < 0.05 32 79 < 0.05
     2 cm < 50 60     70 40
Lymph node metastasis
     Absent 102 32  < 0.05 47 87 < 0.05
     Present  28  59  55 32
Histological stage 
     I 71 20 < 0.05 24 67 < 0.05
     IIA 35 24  27 32
     IIB 12 22  25 9
     IIIA 10 7  21 6
     IIIB 0 1  0 1
     IV 2 7  5 4
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Table 2.  Association between Phospho-Akt 
and PTEN expression
 Positive Negative P value
Phospho-Akt 91 120 
   0.08
PTEN 119 102 
mor size and lymph node metastasis.  There was 
no significant association between Phospho-Akt 
expression and loss of PTEN expression, although 
a tendency was observed (Table 2, P = 0.08). 
 
Disease-free survival and over-all survival 
rates
Patients with Phospho-Akt-positive tumor showed 
a significantly inferior disease-free survival 
rate compared to those with a negative tumor 
(Fig. 3A).  Figure 3B shows the over-all survival 
curves for patients with breast cancer stratiﬁed by 
Phospho-Akt expression.  Patients with Phospho-
Akt-positive tumors showed signiﬁcantly shorter 
Fig. 3.  Disease-free survival curves (A) and over-all survival curves (B) of breast cancer patients. Patients with Phos-
pho-Akt positive tumors are signiﬁcantly inferior to those with Phospho-Akt negative tumors in both disease-free 
survival and over-all survival.  mo, month.  [   ], number of subjects.
over-all survivals than those with Phospho-Akt-
negative tumors.  Furthermore, patients with 
PTEN-positive expression had signiﬁcantly better 
disease-free survival rate than those with PTEN-
negative expression (Fig. 4A).  There was a sig-
nificant difference in over-all survival between 
patients with PTEN-positive and -negative expres-
Fig. 4.  Disease-free survival curves (A) and survival curves (B) of breast cancer patients. Patients with PTEN posi-
tive tumors show higher results than those with PTEN negative tumors in both disease-free survival and over all sur-
vival.  mo, month.  [   ], number of subjects.
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sions (Fig. 4B).  For further analysis of survival 
in relation to Phospho-Akt and PTEN expression, 
patients were classiﬁed into the following groups: 
Group A, positive expression in both Phospho-
Akt and PTEN (Fig. 5A: n = 38, Fig. 5B: n = 44); 
Group B, positive in Phospho-Akt and negative in 
PTEN (Fig. 5A: n = 38, Fig. 5B: n = 47); Group 
C, negative in Phospho-Akt and positive in PTEN 
(Fig. 5A: n = 73, Fig. 5B: n = 75); and Group D, 
negative in both Phospho-Akt and PTEN (Fig. 
5A: n = 51, Fig. 5B: n = 55).  Disease-free sur-
vival and over-all survival of patients in each 
group are shown in Fig. 5.  For both disease-free 
survival and over-all survival, patients in Group B 
had worse results than those in the other groups. 
Both disease-free survival and over-all survival of 
patients in Group C were signiﬁcantly better than 
those in the other groups.  Additionally, there was 
no signiﬁcant association between Groups A and 
D in disease-free survival (P = 0.9176) and over-
all survival time (P = 0.8144).
 
Multivariate analysis 
To determine which of the many covariates in the 
factors listed in Table 3 were important prognos-
tic factors of disease-free survival, a multivariate 
analysis with a Cox regression analysis was done. 
Table 3.  Multivariate analysis by the Cox pro-
portion hazard model for disease-free survival 
in 200 patients with breast cancer 
 Hazard  95% P
 ratio  CI value
Age 0.978 0.951–1.007 0.140
Size (2 cm ≥/2 cm <) 0.243 0.086–0.683 0.007
Lymph-node metastasis 0.861 0.360–2.062 0.737
Phospho-AKT 0.368  0.154–0.877  0.024
PTEN 0.588 0.255–1.356 0.212
CI, conﬁdence interval. 
Fig. 5.  Disease-free survival curves (A) and over-all survival curves (B) of breast cancer patients. The disease-free 
survival curve and over-all survival curve of patients who had tumors in Group B were signiﬁcantly lower than those 
of patients who had tumors in Group C.  mo, month.  [   ], number of subjects; +, positive; –, negative.  
The analysis revealed that expression of Phospho-
Akt and tumor size were the independent factors. 
 
Discussion
 
Considerable evidence indicates that PI3-kinase 
regulated signaling pathways play important roles 
in a variety of cellular processes (Khwaja et al., 
1998) and that the protein kinase, Akt, and PTEN 
are important mediators of these effects (Cross 
et al., 1995; Gingras et al., 1998; Hajduch et al., 
1998; Van Weeren et al., 1998).  The role of PI3-
kinase in the suppression of apoptosis and the 
ability of Akt to directly phosphorylate key me-
diators of the apoptotic response provide strong 
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circumstantial evidence for the importance of the 
PI3-kinase-Akt pathway in the aberrant behavior 
of cancer cells.  The tumor suppressor PTEN acts 
as a lipid phosphatase, regulates the PI3-kinase/
Akt-signaling pathway, and modulates cell cycle 
progression and cell survival.  Recent studies have 
shown that the most critical tumor-cell survival 
pathways are those mediated by PI3-kinase (Chan 
et al., 1999; Ling-Ping et al., 1999).  
 In the current study, Phospho-Akt was ob-
served in cytoplasm and nucleus of tumor cells. 
Staining patterns were consistent with reports that 
activated Akt could translocate to the nucleus in 
ectopically Akt-overexpressing cells (Andjelkovic 
et al., 1997; Meier et al., 1997).  As reported pre-
viously, the PI3-kinase pathway is an essential 
survival signaling pathway for various human 
cancers, including carcinomas of the colon, pros-
tate, ovary, pancreas and lung (Maulik et al., 
2002; Mei Sun et al., 2001; Roy et al., 2002). 
 It is known that patients with both estrogen 
receptor (ER)- and progesterone receptor (PgR)-
negative tumors experienced signiﬁcantly shorter 
disease-free survival  compared to those who’s tu-
mors were positive in either or both.  The relation-
ship between a dysregulated PI3-kinase pathway 
and reduced ER/PgR expression in human breast 
cancers has been reported previously (Depowski 
et al., 2001; Shi et al., 2003).  Kappes et al. (2001) 
reported that there was a significant correlation 
between PI3-kinase pathway abnormalities and 
the hormone receptors.  However, there was no 
apparent correlation between these factors in our 
study (data not shown), though the precise mecha-
nism behind this observation is not entirely clear. 
It has been noted by others that increased Akt 
mRNA correlates with ER-negative breast tumors 
(Nakatani et al., 1999) and increased ER α activ-
ity, which results in tamoxifen resistance (Camp-
bell et al., 2001). 
  It is reported that a loss of expression of the 
PTEN gene protein product is associated with a 
poor outcome in breast cancer (Depowski et al., 
2001).  In the current study, PTEN expression in-
versely correlated with the progression of breast 
cancer.  Patients with PTEN positive breast can-
cer survived signiﬁcantly longer than those with 
a PTEN negative tumor.  Furthermore, Phospho-
Akt expression and loss of PTEN expression were 
frequently observed in patients with advanced 
breast cancer.  Patients with Phospho-Akt-nega-
tive and PTEN-positive tumors showed the best 
prognoses, whereas those with Phospho-Akt posi-
tive and PTEN negative tumors showed the worst. 
Therefore, monitoring the status of Phosph-Akt 
and PTEN protein expression might predict sur-
vival in patients with breast cancer.
 The Akt phosphorylation status in each 
carcinoma case can monitor aspects of malignan-
cies such as cell proliferation rate, resistance to 
chemotherapy and irradiation, invasion and me-
tastasis, and patient prognosis (Brognard et al., 
2001; Clark et al., 2002; Itoh et al., 2002; Semba 
et al., 2002).  At present, no speciﬁc inhibitor for 
Akt is available, though the PI3-kinase inhibitor, 
LY294002, is widely used in laboratories.  It can 
be speculated that LY294002 inhibits some other 
downstream effectors of PI3-kinase in addition 
to Akt; the MAPK cascade and small G protein, 
Rac/Cdc42, are reported to be downstream of Akt 
(Cross et al., 1995).  Izuishi et al. (2000) reported 
that LY294002 administration with tumor em-
bolization may be a new therapeutic strategy for 
patients with pancreatic cancer.  These findings 
suggest the possibility of treating human malig-
nancy using the PI3-kinase inhibitor.  Our results 
indicate that activation of the PI3-kinase pathway 
is a common occurrence in human breast cancers, 
especially in more advanced stages.  Thus, regu-
lating the PI3-kinase pathway could be of beneﬁt 
and may increase the effectiveness of therapies for 
patients with breast cancer.  
 In conclusion, Phospho-Akt/PTEN expres-
sion status could be a deﬁnitive prognostic factor 
in clinical breast cancer.  Further studies concern-
ing the regulation of the PI3-kinase pathway in 
breast cancer are urgently required.
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